| 1 |
Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors [J]. J Cancer Epidemiol, 2013, 2013: 965212.
|
| 2 |
Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients [J]. Ann Surg Oncol, 2012, 19(6): 1874-1880.
|
| 3 |
Lloyd RV. Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the pituitary gland [J]. IARC Sci Publ, 1990, 99(99): 499-537.
|
| 4 |
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma [J]. Cell, 2014, 159(3): 676-690.
|
| 5 |
Lang BH, Lo CY, Chan WF, et al. Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome [J]. World J Surg, 2006, 30(5): 752-758.
|
| 6 |
Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors [J]. JAMA Oncol, 2016, 2(8): 1023-1029.
|
| 7 |
Chang HY, Lin JD, Chou SC, et al. Clinical presentations and outcomes of surgical treatment of follicular variant of the papillary thyroid carcinomas [J]. J Clin Oncol, 2006, 36(11): 688-693.
|
| 8 |
Chakraborty A, Narkar A, Mukhopadhyaya R, et al. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion [J]. Endocr Pathol, 2012, 23(2): 83-93.
|
| 9 |
Vivero M, Kraft S, Barletta JA. Risk stratification of follicular variant of papillary thyroid carcinoma [J]. Thyroid, 2013, 23(3): 273-279.
|
| 10 |
Pillal S, Gopalan V, Smith RA, et al. Diffuse sclerosing variant of papillary thyroid carcinoma--an update of its clinicopathological features and molecular biology [J]. Crit Rev Oncol Hematol, 2015, 94(1): 64-73.
|
| 11 |
Rivera M, Ricarte-filho J, Knauf J, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns [J]. Mod Pathol, 2010, 23(9): 1191-1200.
|
| 12 |
舒启沛, 方可敬, 郭燕丽. 弥漫硬化型甲状腺乳头状癌的影像学研究进展 [J]. 临床超声医学杂志, 2019, 21(10): 766-768.
|
| 13 |
Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer [J]. Oncogene, 2004, 23(44): 7436-7440.
|
| 14 |
Joung JY, Kim TH, Jeong DJ, et al. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications [J]. Histopathology, 2016, 69(1): 45-53.
|
| 15 |
Sheu SY, Schwertheim S, Worm K, et al. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements [J]. Mod Pathol, 2007, 20(7): 779-787.
|
| 16 |
Besset V, Scott RP, Ibanez CF. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase [J]. J Biol Chem, 2000, 275(50): 39159-39166.
|
| 17 |
Costa V, Esposito R, Ziviello C, et al. New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma [J]. Oncotarget, 2015, 6(13): 11242-11251.
|
| 18 |
Hawk WA, Hazard JB. The many appearances of papillary carcinoma of the thyroid [J]. Cleve Clin Q, 1976, 43(4): 207-215.
|
| 19 |
Kakudo K, Bychkov A, BAI Y, et al. The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives [J]. Pathol Int, 2018, 68(12): 641-664.
|
| 20 |
Ito Y, Hirokawa M, Fukushima M, et al. Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan [J]. World J Surg, 2008, 32(7): 1535-1543; discussion 1544-1545.
|
| 21 |
Ghossein RA, Leboeuf R, Patel KN, et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications [J]. Thyroid, 2007, 17(7): 655-661.
|
| 22 |
Urano M, Kiriyama Y, Takakuwa Y, et al. Tall cell variant of papillary thyroid carcinoma: Its characteristic features demonstrated by fine-needle aspiration cytology and immunohistochemical study [J]. Diagn Cytopathol, 2009, 37(10): 732-737.
|
| 23 |
Beninato T, Scognamiglio T, Kleiman DA, et al. Ten percent tall cells confer the aggressive features of the tall cell variant of papillary thyroid carcinoma [J]. Surgery, 2013, 154(6): 1331-1336.
|
| 24 |
郝亚琳, 金城, 王家东. 甲状腺乳头状癌高细胞亚型 [J]. 国际耳鼻咽喉头颈外科杂志, 2013, 31(1): 30-33.
|
| 25 |
Liu C, Chen T, Liu Z. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis [J]. World J Surg Oncol, 2016, 14(1): 241.
|
| 26 |
Costa NR, Paulo P, Caffrey T, et al. Impact of MUC1 mucin downregulation in the phenotypic characteristics of MKN45 gastric carcinoma cell line [J]. PLoS One, 2011, 6(11): e26970.
|
| 27 |
Huang L, Chen D, Liu D, et al. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin [J]. Cancer Res, 2005, 65(22): 10413-10422.
|
| 28 |
Thompson EJ, Shanmugam K, Hattrup CL, et al. Tyrosines in the MUC1 cytoplasmic tail modulate transcription via the extracellular signal-regulated kinase 1/2 and nuclear factor-kappaB pathways [J]. Mol Cancer Res, 2006, 4(7): 489-497.
|
| 29 |
Singh PK, Behrens ME, Eggers JP, et al. Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression [J]. J Biol Chem, 2008, 283(40): 26985-26995.
|
| 30 |
Lin JD, Hsueh C, Huang BY. Papillary thyroid carcinoma with different histological patterns [J]. Chang Gung Med J, 2011, 34(1): 23-34.
|
| 31 |
Nardone HC, Ziober AF, Livolsi VA, et al. c-Met expression in tall cell variant papillary carcinoma of the thyroid [J]. Cancer, 2003, 98(7): 1386-1393.
|
| 32 |
Lim YC, Kang HJ, Moon JH. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell [J]. Oral Oncol, 2014, 50(7): 633-639.
|
| 33 |
Gholamin S, Fiuji H, Maftouh M, et al. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress [J]. Curr Drug Targets, 2014, 15(14): 1302-1311.
|
| 34 |
Kufe DW. Mucins in cancer: function, prognosis and therapy [J]. Nat Rev Cancer, 2009, 9(12): 874-885.
|
| 35 |
Romei C, Eliei R. RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma [J]. Front Endocrinol (Lausanne), 2012, 3(54): 1-8.
|
| 36 |
Adeniran AJ, Zhu Z, GandhiI M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas [J]. Am J Surg Pathol, 2006, 30(2): 216-222.
|
| 37 |
Erler P, Keutgen XM, Crowley MJ, et al. Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer [J]. Surgery, 2014, 156(6): 1342-1450.
|
| 38 |
Lee SH, Jung CK, Bae JS, et al. Liquid-based cytology improves preoperative diagnostic accuracy of the tall cell variant of papillary thyroid carcinoma [J]. Diagn Cytopathol, 2014, 42(1): 11-17.
|
| 39 |
Oh WJ, Lee YS, Cho U, et al. Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features [J]. Korean J Pathol, 2014, 48(3): 201-208.
|
| 40 |
Min HS, Lee C, Jung KC. Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population [J]. J Korean Med Sci, 2013, 28(4): 534-541.
|
| 41 |
Basolo F, Torregrossa L, Giannini IR, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases [J]. J Clin Endocrinol Metab, 2010, 95(9): 4197-4205.
|
| 42 |
Xing M. BRAF mutation in thyroid cancer [J]. Endocr Relat Cancer, 2005, 12(2): 245-262.
|
| 43 |
Bernstein J, Virl RK, Hui P, et al. Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis [J]. Thyroid, 2013, 23(12): 1525-1531.
|
| 44 |
Vasileiadis I, Karakostas E, Charitoudis G, et al. Papillary thyroid microcarcinoma: clinicopathological characteristics and implications for treatment in 276 patients [J]. Eur J Clin Invest, 2012, 42(6): 657-664.
|
| 45 |
International Agency for Research on Cancer. World Cancer Report 2014 [M]. Geneva: WHO, 2015.
|
| 46 |
Vaccarella S, Franceschi S, Bray F, et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis [J]. N Engl J Med, 2016, 375(7): 614-617.
|
| 47 |
Shin JH, Baek JH, Chung J, et al. Ultrasonography Diagnosis and Imaging-Based Management of Thyroid Nodules: Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations [J]. Korean J Radiol, 2016, 17(3): 370-395.
|
| 48 |
Tessler FN, Middleton WD, Grant EG. Thyroid imaging reporting and data system (ti-rads): a user's guide [J]. Radiology, 2018, 287(1): 29-36.
|
| 49 |
中国抗癌协会甲状腺癌专业委员会(CATO). 甲状腺微小乳头状癌诊断与治疗中国专家共识2016版 [J]. 中国肿瘤临床, 2016, 43(10): 405-411.
|